

### This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
<b>Cancer</b>				
Leukemia; lymphoma; multiple myeloma (MM)	Bromodomain containing 2 (BRD2); BRD3; BRD4; c-Myc (MYC)	<p>A study in cell culture and in mice suggests inhibitors of BET bromodomains could help treat hematological malignancies. In a panel of leukemia, lymphoma and MM cell lines, JQ1, an inhibitor of BET domains BRD2, BRD3 and BRD4, decreased both MYC expression and cell proliferation compared with an inactive control compound. In xenograft mouse models of Burkitt's lymphoma, JQ1 decreased MYC expression and tumor growth and increased survival compared with vehicle. Next steps at Constellation Pharmaceuticals Inc. include developing multiple series of small molecule BET bromodomain inhibitors.</p> <p>The company's BET bromodomain inhibitors are in preclinical development for cancer and immunological indications.</p> <p>Tensha Therapeutics Inc. has bromodomain inhibitors in preclinical development for cancer.</p> <p><b>SciBX 4(40); doi:10.1038/scibx.2011.1112</b> Published online Oct. 13, 2011</p>	Patent status undisclosed; Constellation Pharmaceuticals' BET program not currently partnered	<p>Mertz, J.A. <i>et al. Proc. Natl. Acad. Sci. USA</i>; published online Sept. 26, 2011; doi:10.1073/pnas.1108190108</p> <p><b>Contact:</b> Robert J. Sims III, Constellation Pharmaceuticals Inc., Cambridge, Mass. e-mail: <a href="mailto:robert.sims@constellationpharma.com">robert.sims@constellationpharma.com</a></p>